This article is available online at http://dmd.aspetjournals.org
ABSTRACT:Ketamine is a widely used drug for its anesthetic and analgesic properties; it is also considered as a drug of abuse, as many cases of ketamine illegal consumption were reported. Ketamine is Ndemethylated by liver microsomal cytochrome P450 into norketamine. The identification of the enzymes responsible for ketamine metabolism is of great importance in clinical practice. In the present study, we investigated the metabolism of ketamine in human liver microsomes at clinically relevant concentrations. Liver to plasma concentration ratio of ketamine was taken into consideration. Pooled human liver microsomes and human lymphoblastexpressed P450 isoforms were used. N-demethylation of ketamine was correlated with nifedipine oxidase activity (CYP3A4-specific marker reaction), and it was also correlated with S-mephenytoin N-demethylase activity (CYP2B6-specific marker reaction). Orphenadrine, a specific inhibitor to CYP2B6, and ketoconazole, a specific inhibitor to CYP3A4, inhibited the N-demethylation of ketamine in human liver microsomes. In human lymphoblast-expressed P450, the activities of CYP2B6 were higher than those of CYP3A4 and CYP2C9 at three concentrations of ketamine, 0.005, 0.05, and 0.5 mM. When these results were extrapolated using the average relative content of these P450 isoforms in human liver, CYP3A4 was the major enzyme involved in ketamine N-demethylation. The present study demonstrates that CYP3A4 is the principal enzyme responsible for ketamine N-demethylation in human liver microsomes and that CYP2B6 and CYP2C9 have a minor contribution to ketamine N-demethylation at therapeutic concentrations of the drug.Ketamine is a N-methyl-D-aspartate receptor antagonist used in clinical practice since 1970 for its anesthetic, sedative, and analgesic properties. It is frequently used for induction of anesthesia in short term surgical operations, in maintaining anesthesia with other anesthetic agents, and as a postoperative pain relief agent in intensive care units (Nimmo and Clements, 1981;White et al., 1982). In recent years, there is increasing evidence of ketamine abuse, many cases of illegal ketamine consumption, and dependence was reported (Jansen and Darracot-Cankovic, 2001;Moore et al., 2001).Ketamine is N-demethylated by cytochrome P450 (P450 1 ) enzymes in the liver into norketamine (Fig. 1). In humans and animals, norketamine (NK) is considered as the major metabolite (Kaka and Hayton, 1980;Woolf and Adams, 1987), and it may contribute to the analgesic effect following ketamine administration (Shimoyama et al., 1999). In a recent study (Yanagihara et al., 2001), the human liver microsomal enzyme CYP2B6 was identified as the main P450 isoform responsible for the N-demethylation of ketamine in pooled human liver microsomes obtained from 10 donors, at a ketamine concentration of 0.005 mM. The expression of CYP2B6 is very low in comparison with other P450 isoforms (Ͻ1% of total P450). In addition, CYP2B6 shows a large interindiv...